Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents (Note 6)	$ 2,459.2	$ 3,818.5
Short-term investments (Note 6)	109.1	90.1
Accounts receivable, net of allowances of $22.0 (2022) and $22.5 (2021)	6,322.5	6,672.8
Other receivables	1,483.2	1,454.4
Inventories	3,893.0	3,886.0
Prepaid expenses and other	2,697.7	2,530.6
Total current assets	16,964.7	18,452.4
Investments (Note 6)	2,727.3	3,212.6
Goodwill	3,892.0	3,892.0
Other intangibles, net	7,482.4	7,691.9
Deferred tax assets	2,464.9	2,489.3
Property and equipment, net of accumulated depreciation of $10,138.3 (2022) and $9,976.7 (2021)	9,102.7	8,985.1
Other noncurrent assets	4,285.3	4,082.7
Total assets	46,919.3	48,806.0
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,355.9	1,538.3
Accounts payable	1,433.3	1,670.6
Employee compensation	693.1	958.1
Sales rebates and discounts	6,768.7	6,845.8
Dividends payable	0.0	885.5
Income taxes payable	598.3	126.9
Other current liabilities	2,536.7	3,027.5
Total current liabilities	13,386.0	15,052.7
Other Liabilities
Long-term debt	15,152.9	15,346.4
Accrued retirement benefits (Note 8)	1,940.3	1,954.1
Long-term income taxes payable	3,978.1	3,920.0
Deferred tax liabilities	1,286.1	1,733.7
Other noncurrent liabilities	1,713.9	1,644.3
Total other liabilities	24,071.3	24,598.5
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity
Common stock	594.1	596.3
Additional paid-in capital	6,656.3	6,833.4
Retained earnings	9,369.4	8,958.5
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 10)	(4,225.3)	(4,343.1)
Cost of common stock in treasury	(50.5)	(52.7)
Total Eli Lilly and Company shareholders' equity	9,330.8	8,979.2
Noncontrolling interests	131.2	175.6
Total equity	9,462.0	9,154.8
Total liabilities and equity	$ 46,919.3	$ 48,806.0